Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1447 Views
-
Last post by NHE
-
- 0 Replies
- 787 Views
-
Last post by NHE
-
- 0 Replies
- 2170 Views
-
Last post by frodo
-
- 0 Replies
- 1064 Views
-
Last post by NHE
-
- 1 Replies
- 988 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1290 Views
-
Last post by frodo
-
- 0 Replies
- 1554 Views
-
Last post by NHE
-
- 0 Replies
- 1995 Views
-
Last post by vesta
-
- 0 Replies
- 1567 Views
-
Last post by frodo